Сравнение
Icatibant vs. Octreotide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Исследования (прочее)
Исследования (прочее)
Номер CAS
138614-30-9
83150-76-9
Молекулярная масса
1304.52 g/mol
1019.24 g/mol
Период полувыведения
нет данных
1.7 h
Последовательность
нет данных
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Механизм действия
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
5
из них на людях
1
4
Зафиксированные эффекты
1
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
1
2
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Icatibant and Octreotide?
- Icatibant is classified as "Исследования (прочее)", while Octreotide is classified as "Исследования (прочее)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Icatibant or Octreotide?
- The highest available evidence level is "РКИ на людях" for Icatibant and "РКИ на людях" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Icatibant and Octreotide in Germany and the United States?
- Германия: Icatibant — Рецептурный, Octreotide — Рецептурный. США: Icatibant — Рецептурный, Octreotide — Рецептурный. These are factual summaries with source and review date on the individual pages.